Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norvasc Generic Substitution Rate Reaches Nearly 77 Percent

This article was originally published in The Pink Sheet Daily

Executive Summary

Rate has increased nearly five fold since amlodipine generics hit the market.
Advertisement

Related Content

Apotex Launches Generic Norvasc
Apotex Launches Generic Norvasc
Mylan, Pfizer On The Same Side Over FDA Approval Of Pending Norvasc ANDAs
Mylan Launches Generic Norvasc; 180-Day Exclusivity May Be Moot
Mylan Launches Generic Norvasc; 180-Day Exclusivity May Be Moot
Generic Norvasc May Launch Sooner Than Expected Following Appellate Court Ruling

Topics

Advertisement
UsernamePublicRestriction

Register

PS065948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel